Daniel D Karp
Overview
Explore the profile of Daniel D Karp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
3992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thein K, Karp D, Tsimberidou A, Gong J, Sulovic S, Shah J, et al.
Invest New Drugs
. 2025 Feb;
PMID: 39976873
No abstract available.
2.
Nardo M, Gouda M, Reilley M, Biter A, Lim J, Bean S, et al.
J Immunother Precis Oncol
. 2025 Feb;
8(2):89-98.
PMID: 39959251
Introduction: TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and...
3.
Alhalabi O, Gouda M, Milton D, Momin H, Yilmaz B, Stephen B, et al.
Cancer Med
. 2025 Feb;
14(4):e70280.
PMID: 39945382
Background: Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL...
4.
Tang C, Hartley G, Couillault C, Yuan Y, Lin H, Nicholas C, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000133.
PMID: 39886125
Objective: To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with...
5.
Ahmed J, Janku F, Karp D, Piha-Paul S, Tsimberidou A, Yap T, et al.
Cancer
. 2025 Jan;
131(3):e35728.
PMID: 39853679
Background: Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket...
6.
Ahmed J, Stephen B, Khawaja M, Yang Y, Salih I, Barrientos-Toro E, et al.
Gynecol Oncol
. 2025 Jan;
193:73-80.
PMID: 39787747
Introduction: Molecular alterations in the PI3K/AKT and Ras/Raf/MEK/ERK pathways are frequently observed in patients with endometrial cancers. However, mTOR inhibitors, such as temsirolimus, have modest clinical benefits. In addition to...
7.
Holla V, Kahle M, Kim S, Ronaghy A, Yang R, Patel K, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400419.
PMID: 39576951
Purpose: PD-1 inhibition is effective in patients with mismatch repair deficient (dMMR) solid tumors in a tumor-agnostic fashion. However, dMMR testing by immunohistochemistry (IHC) is not routinely performed across tumor...
8.
Karp D, Osburn J, Gouda M
J Immunother Precis Oncol
. 2024 Nov;
7(4):242-246.
PMID: 39524468
No abstract available.
9.
Chang J, Xu X, Shroff G, Comeaux N, Li W, Rodon Ahnert J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39384194
Background: BMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector T-cell activation. Combined anti-GITR, anti-programmed death-1, anti-cytotoxic T-lymphocyte-associated protein 4 antibodies...
10.
Piha-Paul S, Tseng C, Leung C, Yuan Y, Karp D, Subbiah V, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):166.
PMID: 39085400
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients...